Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A series of SynLeptin peptides, particularly, SynLeptin-2 shows remarkable anti-obesity activities which were verified in animal experiments using mice and rabbits. More
Related Reports
Market Research Reports provided by reports.innovaro.com
Aug 2008 - 117 pages - $2,350
Mar 2011 - 23 pages - $250
Apr 2010 - 121 pages - $2,350
Aug 2007 - 87 pages - $1,999
Sep 2011 - 20 pages - $99
Sep 2011 - 59 pages - $99
Nov 2007 - 173 pages - $1,860
Feb 2010 - 62 pages - $1,040
May 2011 - 15 pages - $250
Apr 2009 - 100 pages - $1,040
Your selection
Browse By
- Industry sector
- Advertising
- Business services
- Clinical research
- Communications
- Consultancy
- Distribution
- Event management
- Finance
- Information technology
- Laboratory equipment
- Legal
- Manufacturing
- Market research
- Marketing
- Materials
- Medical education
- Packaging
- Patents
- Pharmacovigilance
- Product development
- Public relations
- Publishers
- Recruitment
- Regulatory affairs
- Research
- Training
- Therapeutic target
- Anorexia
- Anti-oxidant
- Appetite
- Bulimia nervosa
- Cachexia
- Cirrhosis
- Diabetes type I
- Diabetes type II
- Diabetic complications
- Fabry's disease
- Gallbladder disorder (other)
- Gallstones
- Gaucher's disease
- Hepatic protectors
- Hepatic protectors
- Hypercholesterolemia
- Hyperparathyroidism
- Hypertriglyceridemia
- Liver cancer
- Liver disorders (other)
- Metabolic disorder (other)
- Mineral supplement
- Obesity
- Weight loss
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us